

October 26, 1967

Dr. Joseph G. Bird
Director, Division of Clinical Research
Sterling-Winthrop Research Institute
Rensselaer, New York 12144

Dear Joe,

I have spoken to Dr. T. P. S. Watts of Geigy Pharmaceuticals and he believes there should be no problem in obtaining the imipramine for this study. I spoke to him on Monday after his return from a trip and he believes he can give us definite information early next week.

The revised protocol is enclosed. Because the dosage schedule is defined, I have asked Dr. Simeon and Dr. Zaks to begin the next few patients on this new schedule without going through prior imipramine treatment.

By the time that we have the supplies, we should have had experience with this new dosage schedule.

It is kind of you to suggest payment for the expenses of our trip, but these were nominal and can be defrayed from the funds we have already received.

As part of this new protocol, you will note that we have decided to use the Hamilton Rating Scale. This scale has the advantage of widespread use and has been adopted by NIMH for the early clinical program. We have asked Dr. Shapiro, our computer director, to develop a special diagnostic program and this should be available in time to be implemented in the cyclazocine-imipramine study.

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp